Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last --
Change Today 0.00 / 0.00%
Volume 0.0
VIVIMEDLAB On Other Exchanges
Symbol
Exchange
VIVIMEDLAB is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

vivimed labs ltd (VIVIMEDLAB) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VIVIMED LABS LTD (VIVIMEDLAB)

Related News

No related news articles were found.

vivimed labs ltd (VIVIMEDLAB) Related Businessweek News

No Related Businessweek News Found

vivimed labs ltd (VIVIMEDLAB) Details

Vivimed Labs Limited, together with its subsidiaries, manufactures specialty chemicals and pharmaceutical products in India and internationally. It operates through two segments, Speciality Chemicals and Pharmaceuticals. The company offers contractual manufacturing services for APIs and formulations, as well as active ingredients for a range of home, personal care, and industrial products; and manufactures branded formulations. Its products include antibacterials for toothpaste and mouthwash, and neutraceuticals for dental enamel protection for the oral care market; UV-A and UV-B filters for sun care products; skin care ingredients, such as active anti-wrinkle, anti-ageing compounds, anti-oxidants, skin-lightening actives, and emollients; hair dye intermediates, anti-dandruff agents, UV absorbers, hair loss actives, and guar gums for use in hair care products. The company also provides Reversacol photochromic dyes for applications in plastics, films, coatings, and inks; anti-microbial actives for use in a range of applications, such as plastics additives and anti-bacterial hand washes; preservatives for various formulations; photographic chemicals for use in the medical and industrial X-ray imaging, consumer photography, and litho-plate production for the graphic arts industry; and Nisarg range of naturally derived cosmetic ingredients. In addition, it offers ophthalmic, nutraceuticals, and dermatological therapeutic products. Vivimed Labs Limited was incorporated in 1988 and is based in Hyderabad, India.

Founded in 1988

vivimed labs ltd (VIVIMEDLAB) Top Compensated Officers

Director of Research & Development and Direct...
Total Annual Compensation: 2.4M
Compensation as of Fiscal Year 2013.

vivimed labs ltd (VIVIMEDLAB) Key Developments

Vivimed Labs Appoints Umanath Varahabhotla as Additional Director

Vivimed Labs announced that the Board of Directors of the company vide circular resolution have approved the appointment of Umanath Varahabhotla as an Additional Director of the Company.

Vivimed Labs Limited Accepts Resignation of Vaidyanathan M as CFO

Vivimed Labs Ltd. accepted the resignation of Mr. Vaidyanathan M. as Chief Financial Officer of the Company due to personal reasons. The Company is in the process of appointing a new CFO.

Vivimed Labs Limited Announces Unaudited Consolidated and Standalone Financial Results for the Third Quarter and Nine Months Ended December 31, 2014

Vivimed Labs Limited announced unaudited consolidated and standalone financial results for the third quarter and nine months ended December 31, 2014. For the quarter, on consolidated basis the company reported net sales of INR 3,437.089 million against INR 3,352.656 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 418.361 million against INR 366.613 million a year ago. Profit from ordinary activities before tax was INR 224.638 million against INR 210.129 million a year ago. Net profit for the period was INR 205.609 million or INR 12.69 per basic and diluted share against INR 189.881 million or INR 11.72 per basic and diluted share a year ago. EBITDA was INR 603 million compared to INR 536 million a year ago. EBIT was INR 418 million compared to INR 367 million a year ago. For the nine months, on consolidated basis, the company reported net sales of INR 10,238.840 million against INR 9,826.598 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 1,205.263 million against INR 1,058.574 million a year ago. Profit from ordinary activities before tax was INR 611.895 million against INR 632.014 million a year ago. Net profit for the period was INR 541.021 million or INR 33.39 per basic and diluted share against INR 553.523 million or INR 34.16 per basic and diluted share a year ago. EBITDA was INR 1,720 million compared to INR 1,548 million a year ago. For the quarter, on standalone basis, the company reported net sales of INR 1,052.752 million against INR 1,033.997 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 223.064 million against INR 195.934 million a year ago. Profit from ordinary activities before tax was INR 51.661 million against INR 86.57 million a year ago. Net profit for the period was INR 41.329 million or INR 2.55 per basic and diluted share against INR 69.256 million or INR 4.27 per basic and diluted share a year ago. For the nine months, on standalone basis, the company reported net sales of INR 3,037.354 million against INR 3,041.834 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 638.409 million against INR 571.088 million a year ago. Profit from ordinary activities before tax was INR 175.054 million against INR 276.914 million a year ago. Net profit for the period was INR 133.375 million or INR 8.23 per basic and diluted share against INR 221.531 million or INR 13.67 per basic and diluted share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VILA:IN 328.45 INR 0.00

VIVIMEDLAB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VIVIMEDLAB.
View Industry Companies
 

Industry Analysis

VIVIMEDLAB

Industry Average

Valuation VIVIMEDLAB Industry Range
Price/Earnings 8.1x
Price/Sales 0.4x
Price/Book 1.1x
Price/Cash Flow 3.9x
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VIVIMED LABS LTD, please visit www.vivimedlabs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.